Single User License
INR 101895
Site License
INR 203790
Corporate User License
INR 305685

Service Tax Additional

select a format
Price

Single User License
USD 1500
Site License
USD 3000
Corporate User License
USD 4500

Alternatively

Request a quote
Request a Customized research
Request for Sample Report





Recent Viewed Reports


Why Ken Reasearch?


Testimonials

While we still are studying and analysing your reports about Vietnam & Thailand, we would like to convey to your research team that they have done a very good job in compiling so much of information together. We hope to see more of such well researched reports. All the best & keep it up. ... "Prashant Bhagwat,General Manager, Mahindra"

We would like to appreciate Ken Research for their great efforts and wonderful support in providing the Market Intelligence Report for ITPC. The information, statistics and research are well understandable and very clear to the point. We are happy with Ken research for their good client service, on-time delivery of the report and as said the report itself. Thank you Ken research for bringing the valuable output for us. We would be looking forward to have more research with you in the near future. Wish you a success in your business!... "Jestin Mathew, Indonesian Trade Promotion Center"

The Report was very interesting and useful for me... "Marketing Manager, Western Union Business Solutions"

Ken Research completed the report successfully with tough deadline and large requirement. Really appreciate it... "Sales Manager, Largest India Aesthetic Laser Manufacturer"

We found the report really useful in understanding the complex Indian market and it provided lots of high quality insights. On the basis of this we commissioned Ken to produce a bespoke follow up to answer some specific questions about our market. This is now being used to help develop our marketing and sales strategy. We were very pleased with the comprehensive coverage, detail provided and actionable insights.... "Owner, Therefore Consulting UK"


Teva Pharmaceutical Industries Limited-Product Pipeline Review-2015

Teva Pharmaceutical Industries Limited-Product Pipeline Review-2015


  Request for Sample Report

Executive Summary

Teva Pharmaceutical Industries Limited-Product Pipeline Review-2015

Summary

Global Markets Direct's, 'Teva Pharmaceutical Industries Limited-Product Pipeline Review-2015', provides an overview of the Teva Pharmaceutical Industries Limited's pharmaceutical research and development focus.

This report provides comprehensive information on the current therapeutic developmental pipeline of Teva Pharmaceutical Industries Limited's, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. It also reviews latest updates, and featured news and press releases, along with special features on late-stage and discontinued projects.

Global Markets Direct's report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct's proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Direct's team. Drug profiles/records featured in the report undergoes periodic updation following a stringent set of processes that ensures that all the profiles are updated with the latest set of information. Additionally, processes including live news & deals tracking, browser based alert-box and clinical trials registries tracking ensure that the most recent developments are captured on a real time basis.

The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.

Scope

The report provides brief overview of Teva Pharmaceutical Industries Limited including business description, key information and facts, and its locations and subsidiaries

The report reviews current pipeline of Teva Pharmaceutical Industries Limited's human therapeutic division and enlists all their major and minor projects

The report features product description and descriptive mechanism of action for key pipeline products along with the product's developmental history and major milestones

Special feature on out-licensed and partnered product portfolio

The report summarizes all the dormant and discontinued pipeline projects

Latest company statement

Latest news and deals relating to the Teva Pharmaceutical Industries Limited's pipeline products

Reasons To Buy

Evaluate Teva Pharmaceutical Industries Limited's strategic position with total access to detailed information on its product pipeline

Assess the growth potential of Teva Pharmaceutical Industries Limited in its therapy areas of focus

Identify new drug targets and therapeutic classes in the Teva Pharmaceutical Industries Limited's R&D portfolio and develop key strategic initiatives to reinforce pipeline in those areas

Exploit in-licensing opportunities by identifying windows of opportunity to fill portfolio gaps

Develop strategic initiatives by understanding the focus areas of Teva Pharmaceutical Industries Limited and exploit collaboration and partnership opportunities

Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage

Plan mergers and acquisitions effectively by identifying the most promising pipeline of Teva Pharmaceutical Industries Limited

Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope

Explore the dormant and discontinued projects of Teva Pharmaceutical Industries Limited and identify potential opportunities in those areas

Avoid Intellectual Property Rights related issues

Table of Contents

Table of Contents 2

List of Tables 5

List of Figures 5

Teva Pharmaceutical Industries Limited Snapshot 6

Teva Pharmaceutical Industries Limited Overview 6

Key Information 6

Key Facts 6

Teva Pharmaceutical Industries Limited-Research and Development Overview 7

Key Therapeutic Areas 7

kTeva Pharmaceutical Industries Limited-Pipeline Review 11

Teva Pharmaceutical Industries Limited-Pipeline Review 12

Pipeline Products by Stage of Development 12

Pipeline Products-Monotherapy 13

Pipeline Products-Combination Treatment Modalities 14

Pipeline Products-Partnered Products 15

Pipeline Products-Out-Licensed Products 17

Teva Pharmaceutical Industries Limited-Pipeline Products Glance 19

Teva Pharmaceutical Industries Limited-Late Stage Pipeline Products 19

Teva Pharmaceutical Industries Limited-Clinical Stage Pipeline Products 22

Teva Pharmaceutical Industries Limited-Early Stage Pipeline Products 24

Teva Pharmaceutical Industries Limited-Unknown Stage Pipeline Products 26

Teva Pharmaceutical Industries Limited-Drug Profiles 27

(ethinylestradiol + levonorgestrel) 27

glatiramer acetate 28

hydrocodone bitartrate ER 30

laquinimod sodium 32

lipegfilgrastim 36

(fluticasone propionate + salmeterol xinafoate) 37

albutropin 38

armodafinil 39

beclomethasone dipropionate 41

bendamustine hydrochloride 43

fluticasone propionate 46

pridopidine hydrochloride 47

rasagiline mesylate 49

reslizumab 50

omacetaxine mepesuccinate 51

TEV-48125 54

TV-1380 56

TV-45070 57

atropine sulfate 58

CEP-37250 59

CEP-37440 60

irdabisant 61

TEV-90110 62

TEV-90112 63

TV-46017 64

TV-46139 65

TV-46763 66

TV-48108 67

CEP-11981 68

CEP-28122 69

CEP-33779 70

Drug for Undisclosed Indication 71

MDT-011 72

MetPril 73

modafinil next generation 74

NP-201 75

NP-202 76

Recombinant Protein to Inhibit IL-17A for Psoriasis 77

Recombinant Protein to Target CD38 for Multiple Myeloma 78

Small Molecule-2 to Antagonize 5-HT6 for CNS Disorders 79

(acetaminophen + immediate release opioid 1) 80

(acetaminophen + immediate release opioid 2) 81

AD-3 82

AD-4 83

Fixed Dose Combination-3 for HIV 84

Fixed Dose Combination-4 for HIV 85

risperidone LAI 86

Small Molecule to Inhibit Poly (ADP-Ribose) Polymerase 1 for Undisclosed Indication 87

Small Molecule-1 to Antagonize 5-HT6 Receptor for CNS Disorders 88

Drug for Dependence 89

Drug For Parkinson Disease 90

Teva Pharmaceutical Industries Limited-Pipeline Analysis 91

Teva Pharmaceutical Industries Limited-Pipeline Products by Target 91

Teva Pharmaceutical Industries Limited-Pipeline Products by Route of Administration 94

Teva Pharmaceutical Industries Limited-Pipeline Products by Molecule Type 95

Teva Pharmaceutical Industries Limited-Pipeline Products by Mechanism of Action 96

Teva Pharmaceutical Industries Limited-Recent Pipeline Updates 99

Teva Pharmaceutical Industries Limited-Dormant Projects 118

Teva Pharmaceutical Industries Limited-Discontinued Pipeline Products 121

Discontinued Pipeline Product Profiles 121

Teva Pharmaceutical Industries Limited-Company Statement 125

Teva Pharmaceutical Industries Limited-Locations And Subsidiaries 127

Head Office 127

Other Locations & Subsidiaries 127

Appendix 136

Methodology 136

Coverage 136

Secondary Research 136

Primary Research 136

Expert Panel Validation 136

Contact Us 136

Disclaimer 137

List of Tables

Teva Pharmaceutical Industries Limited, Key Information 10

Teva Pharmaceutical Industries Limited, Key Facts 10

Teva Pharmaceutical Industries Limited-Pipeline by Indication, 2015 13

Teva Pharmaceutical Industries Limited-Pipeline by Stage of Development, 2015 16

Teva Pharmaceutical Industries Limited-Monotherapy Products in Pipeline, 2015 17

Teva Pharmaceutical Industries Limited-Combination Treatment Modalities in Pipeline, 2015 18

Teva Pharmaceutical Industries Limited-Partnered Products in Pipeline, 2015 19

Teva Pharmaceutical Industries Limited-Partnered Products/ Combination Treatment Modalities, 2015 20

Teva Pharmaceutical Industries Limited-Out-Licensed Products in Pipeline, 2015 21

Teva Pharmaceutical Industries Limited-Out-Licensed Products/ Combination Treatment Modalities, 2015 22

Teva Pharmaceutical Industries Limited-Pre-Registration, 2015 23

Teva Pharmaceutical Industries Limited-Filing rejected/Withdrawn, 2015 24

Teva Pharmaceutical Industries Limited-Phase III, 2015 25

Teva Pharmaceutical Industries Limited-Phase II, 2015 26

Teva Pharmaceutical Industries Limited-Phase I, 2015 27

Teva Pharmaceutical Industries Limited-Preclinical, 2015 28

Teva Pharmaceutical Industries Limited-Discovery, 2015 29

Teva Pharmaceutical Industries Limited-Unknown, 2015 30

Teva Pharmaceutical Industries Limited-Pipeline by Target, 2015 96

Teva Pharmaceutical Industries Limited-Pipeline by Route of Administration, 2015 98

Teva Pharmaceutical Industries Limited-Pipeline by Molecule Type, 2015 99

Teva Pharmaceutical Industries Limited-Pipeline Products by Mechanism of Action, 2015 101

Teva Pharmaceutical Industries Limited-Recent Pipeline Updates, 2015 103

Teva Pharmaceutical Industries Limited-Dormant Developmental Projects,2015 122

Teva Pharmaceutical Industries Limited-Discontinued Pipeline Products, 2015 125

Teva Pharmaceutical Industries Limited, Other Locations 131

Teva Pharmaceutical Industries Limited, Subsidiaries 132

List of Figures

Teva Pharmaceutical Industries Limited-Pipeline by Top 10 Indication, 2015 12

Teva Pharmaceutical Industries Limited-Pipeline by Stage of Development, 2015 16

Teva Pharmaceutical Industries Limited-Monotherapy Products in Pipeline, 2015 17

Teva Pharmaceutical Industries Limited-Combination Treatment Modalities in Pipeline, 2015 18

Teva Pharmaceutical Industries Limited-Partnered Products in Pipeline, 2015 19

Teva Pharmaceutical Industries Limited-Pipeline by Top 10 Target, 2015 95

Teva Pharmaceutical Industries Limited-Pipeline by Top 10 Route of Administration, 2015 98

Teva Pharmaceutical Industries Limited-Pipeline by Top 10 Molecule Type, 2015 99

Teva Pharmaceutical Industries Limited-Pipeline Products by Top 10 Mechanism of Action, 2015 100

Single User License:
Report can be used by individual purchaser only

Site License:
Report can be shared by unlimited users within one corporate location, e.g. a regional office

Corporate User License:
Report can be shared globally by unlimited users within the purchasing corporation e.g. all employees of a single company

To know more information on Purchase by Section, please send a mail to query [@] kenresearch.com
 

Current R&D Portfolio of Teva Pharmaceutical Industries Limited; Teva Pharmaceutical Industries Limited - Key Therapeutics; Teva Pharmaceutical Industries Limited - Pipeline Overview and Promising Molecules; Teva Pharmaceutical Industries Limited - News; Teva Pharmaceutical Industries Limited - Latest Updates; Teva Pharmaceutical Industries Limited - Pipeline; Teva Pharmaceutical Industries Limited - Discontinued/Dormant Projects


Related Products in vertical
Other reports by publisher
Ken Research Pvt. Ltd. 27A, Tower B-2, Spaze I Tech Business Park, Sohna Road, sector 49
     Gurgaon, Haryana - 122001, India
+91 1244230204

download

Company Brochure

Engage with Us

query [@] kenresearch.com